ES2479544T1 - Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias - Google Patents

Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias Download PDF

Info

Publication number
ES2479544T1
ES2479544T1 ES12701941.2T ES12701941T ES2479544T1 ES 2479544 T1 ES2479544 T1 ES 2479544T1 ES 12701941 T ES12701941 T ES 12701941T ES 2479544 T1 ES2479544 T1 ES 2479544T1
Authority
ES
Spain
Prior art keywords
cell
cells
dose
million
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES12701941.2T
Other languages
English (en)
Spanish (es)
Inventor
Eleuterio Lombardo
Wilfred DALEMANS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix NV
Tigenix SA
Original Assignee
Tigenix NV
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix NV, Tigenix SA filed Critical Tigenix NV
Publication of ES2479544T1 publication Critical patent/ES2479544T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES12701941.2T 2011-01-12 2012-01-12 Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias Pending ES2479544T1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11250025 2011-01-12
EP11250025 2011-01-12
PCT/IB2012/000097 WO2012095743A2 (en) 2011-01-12 2012-01-12 Methods and compositions for use in intralymphatic cellular therapies

Publications (1)

Publication Number Publication Date
ES2479544T1 true ES2479544T1 (es) 2014-08-20

Family

ID=45558792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12701941.2T Pending ES2479544T1 (es) 2011-01-12 2012-01-12 Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias

Country Status (6)

Country Link
US (1) US20140154274A1 (enExample)
EP (1) EP2663316A2 (enExample)
JP (2) JP6018081B2 (enExample)
KR (1) KR101900664B1 (enExample)
ES (1) ES2479544T1 (enExample)
WO (1) WO2012095743A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20150104470A1 (en) * 2013-10-11 2015-04-16 Neil H. Riordan Immune modulation by peri-lymphatic or intra-lymphatic cell therapy
US20170121685A1 (en) * 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
KR20190018420A (ko) * 2016-05-06 2019-02-22 각코우호징 오사카 이카야쿠카 다이가쿠 염증성 질환 치료용 줄기세포의 기능 강화를 위한 스타틴 봉입 나노입자 제제, 및 이를 함유하는 염증성 질환 치료용 기능 강화 줄기세포
JP6788003B2 (ja) * 2016-08-26 2020-11-18 学校法人大阪医科薬科大学 スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤
WO2021075525A1 (ja) 2019-10-17 2021-04-22 テルモ株式会社 炎症性疾患を処置するための細胞培養物
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2005097147A1 (en) * 2004-03-30 2005-10-20 Boston Scientific Limited (Incorporated In Ireland) Restenosis therapy using mesenchymal stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
SG10202001007TA (en) * 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
EP2303293A1 (en) * 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CN107090437A (zh) * 2009-03-06 2017-08-25 国立大学法人三重大学 用于增强t细胞功能的方法
HUE031921T2 (en) * 2009-07-09 2017-08-28 Tigenix S A U Methods and preparations for use in cell therapy
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells

Also Published As

Publication number Publication date
JP6018081B2 (ja) 2016-11-02
KR101900664B1 (ko) 2018-09-21
WO2012095743A3 (en) 2012-11-01
JP2014502628A (ja) 2014-02-03
WO2012095743A2 (en) 2012-07-19
EP2663316A2 (en) 2013-11-20
JP2017035094A (ja) 2017-02-16
US20140154274A1 (en) 2014-06-05
KR20140127139A (ko) 2014-11-03

Similar Documents

Publication Publication Date Title
RU2012104529A (ru) Способы и композиции для применения в клеточной терапии
JP2012532859A5 (enExample)
Helissey et al. Chronic inflammation and radiation-induced cystitis: molecular background and therapeutic perspectives
Terzic et al. Stem cell therapy for heart failure: ensuring regenerative proficiency
Seo et al. The immunomodulatory effects of mesenchymal stem cells in prevention or treatment of excessive scars
JP2014502628A5 (enExample)
Zhang et al. ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C/VEGFR-3-dependent mechanism and inhibiting the NF-κ B pathway by the secretome
MX2018012605A (es) Administracion de vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular.
AR077896A1 (es) Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
Nam et al. Intraperitoneal infusion of mesenchymal stem cell attenuates severity of collagen antibody induced arthritis
van der Helm et al. Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers
Prado et al. Combination of stem cells from deciduous teeth and electroacupuncture for therapy in dogs with chronic spinal cord injury: A pilot study
MX2023008809A (es) ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
EA201590582A1 (ru) Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения
Dang et al. Aging microenvironment in osteoarthritis focusing on early-stage alterations and targeted therapies
Adamowicz et al. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials
Muthu et al. What is the clinically significant ideal mesenchymal stromal cell count in the management of osteoarthritis of the knee?–Meta-analysis of randomized controlled trials
AR111491A1 (es) Métodos para tratar enfermedades pediátricas
WO2012095743A2 (en) Methods and compositions for use in intralymphatic cellular therapies
Secades Probably role of citicoline in stroke rehabilitation: review of the literature
Hou et al. Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis
Kim et al. Paradoxical effects of human adipose tissue-derived mesenchymal stem cells on progression of experimental arthritis in SKG mice
BR112015022565A2 (pt) composições e métodos para aumentar o potencial terapêutico das células tronco
Cao et al. Mesenchymal stem cells prevent restraint stress-induced lymphocyte depletion via interleukin-4